高血压治疗中ACE抑制剂:用还是不用?
本综述比较高血压及高血压合并强适应证患者中ACE抑制剂与ARB的疗效和不良事件。两者在血压替代终点及全因死亡、心血管死亡、心肌梗死、心衰、卒中、终末期肾病等结局上无差异,但ACE抑制剂仍与咳嗽及极低风险血管性水肿和死亡相关,因不良事件导致的总体停药率ARB更低。综合风险获益分析,目前几乎没有理由在高血压或其强适应证中使用ACE抑制剂。
要点
- 高血压及合并强适应证患者中,ACE抑制剂与ARB在死亡、心梗、心衰、卒中、终末期肾病等结局上无差异。
- ACE抑制剂仍与咳嗽及极低风险血管性水肿和死亡相关,ARB因不良事件停药率更低。
- 综合风险获益,目前几乎没有理由在高血压或其强适应证中使用ACE抑制剂。
核心结论
- 在高血压及高血压合并强适应证患者中,ACE抑制剂与ARB在血压替代终点及全因死亡、心血管死亡、心肌梗死、心衰、卒中、终末期肾病等结局上无差异。
- ACE抑制剂仍与咳嗽及极低风险血管性水肿和死亡相关,ARB因不良事件总体停药率更低。
- 综合风险获益分析表明,目前几乎没有理由在高血压或其强适应证中使用ACE抑制剂。
研究设计与样本
- 本综述旨在比较ACE抑制剂与ARB在患者中的结局和不良事件。
主要发现
- 高血压及高血压合并强适应证患者中,ARB与ACE抑制剂在血压替代终点及全因死亡、心血管死亡、心肌梗死、心衰、卒中、终末期肾病等结局上无差异。
- ACE抑制剂仍与咳嗽及极低风险血管性水肿和死亡相关。
- ARB因不良事件导致的总体停药率低于ACE抑制剂。
临床怎么用
- 综合疗效相当但ARB不良事件更少,风险获益分析提示目前几乎没有理由在高血压或其强适应证中使用ACE抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most guidelines for the management of patients with cardiovascular disease recommend angiotensin-converting enzyme (ACE) inhibitors as first-choice therapy, whereas angiotensin receptor blockers (ARBs) are merely considered an alternative for ACE inhibitor-intolerant patients. The aim of this review was to compare outcomes and adverse events between ACE inhibitors and ARBs in patients. In patients with hypertension and hypertension with compelling indications, we found no difference in efficacy between ARBs and ACE inhibitors with regard to the surrogate endpoint of blood pressure and outcomes of all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. However, ACE inhibitors remain associated with cough and a very low risk of angioedema and fatalities. Overall withdrawal rates because of adverse events are lower with ARBs than with ACE inhibitors. Given the equal outcome efficacy but fewer adverse events with ARBs, risk-to-benefit analysis in aggregate indicates that at present there is little, if any, reason to use ACE inhibitors for the treatment of hypertension or its compelling indications.
引用
- Messerli FH, Bangalore S, Bavishi C, et al. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol. 2018. PMID: 29598869. doi:10.1016/j.jacc.2018.01.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。